Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

oxarc, inc. - carbon dioxide (unii: 142m471b3j) (carbon dioxide - unii:142m471b3j) - carbon dioxide 990 ml in 1 l

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

airgas nor pac inc - carbon dioxide (unii: 142m471b3j) (carbon dioxide - unii:142m471b3j) - carbon dioxide 992 ml in 1 l

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

red ball oxygen co., inc. - carbon dioxide (unii: 142m471b3j) (carbon dioxide - unii:142m471b3j) - carbon dioxide 990 ml in 1 l

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

oxarc, llc - carbon dioxide (unii: 142m471b3j) (carbon dioxide - unii:142m471b3j) - carbon dioxide 990 ml in 1 l

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

general air service & supply co - carbon dioxide (unii: 142m471b3j) (carbon dioxide - unii:142m471b3j) - carbon dioxide 50 ml in 1 l

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

aero all gas company - carbon dioxide (unii: 142m471b3j) (carbon dioxide - unii:142m471b3j) - carbon dioxide 990 ml in 1 l

Irska - engleski - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carboplatin - concentrate for solution for infusion - 10 milligram(s)/millilitre - platinum compounds; carboplatin

Irska - engleski - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - carboplatin - concentrate for solution for infusion - 10 milligram(s)/millilitre - platinum compounds; carboplatin

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

teva parenteral medicines, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously tr

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

teva parenteral medicines, inc. - carboplatin (unii: bg3f62ond5) (carboplatin - unii:bg3f62ond5) - carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. one established combination regimen consists of carboplatin and cyclophosphamide. two randomized controlled studies conducted by the ncic and swog with carboplatin versus cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see clinical studies ). there is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long-term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously tr